AI Article Synopsis
- Basal cell carcinoma (BCC) is a common skin cancer that can be effectively treated with photodynamic therapy (PDT), which has low side effects and good response rates.
- In a study analyzing 234 superficial BCC cases treated with PDT, 73% achieved "high clearance" at a six-month follow-up, but 16% of those cleared lesions recurred within 24 months.
- The study found that larger and head/neck BCCs had a greater likelihood of partial responses and recurrences, indicating the need for additional treatments in some cases.
Article Abstract
Background: Basal cell carcinoma (BCC) is one of the most common skin cancers. Photodynamic therapy (PDT) is a first line therapy option for superficial BCCs, providing good response and low side effects. The aim of current study is to evaluate the clinicopathological features associated with partial responses or recurrences of BCCs treated with one cycle-PDT (two sessions, one week apart).
Methods: Superficial BCCs treated with PDT between 2016 and 2019 were analyzed. At the 6-month follow-up visit, BCCs were subdivided in "high clearance" or "partial response", based on clinical and/or dermoscopic examination. "High clearance" lesions underwent 24-month follow-up visit and were assigned to "sustained clearance" or "recurrence" groups. Information about age, sex, site, size of lesions, skin biopsy and multiple lesions were collected and the association with the outcomes were estimated with multivariable logistic models.
Results: 234 superficial BCCs from 216 patients were analyzed. At the 6-month follow-up visit, 171 out of 234 BCCs (73%) presented a "high clearance", while 63 lesions (27%) showed a "partial response". 28 out of 171 high clearance BCCs (16%) presented a recurrence within 24 months. When "partial response" is compared with the "high clearance" or "sustained clearance" group, a significant difference in mean superficial size of lesions is detected, with higher values in "partial response". Head and neck BCCs have a double risk of recurrence within 24 months.
Conclusions: PDT is a good therapeutic option for superficial BCCs, even though BCCs of head and neck have a higher risk of recurrences and larger BCCs could need a supplementary treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pdpdt.2022.102727 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dermoscopy of Basal Cell Carcinoma Part 2: Dermoscopic Findings by Lesion Subtype, Location, Age of Onset, Size and Patient Phototype.
Cancers (Basel)
January 2025
Department of Dermatology, Institute of Medical Sciences, Medical College, Rzeszow University, 35-310 Rzeszow, Poland.
Basal cell carcinoma (BCC) is the most prevalent type of skin cancer worldwide. Despite its low metastatic potential, certain subtypes present an aggressive clinical course. Part II focuses on the different dermoscopic patterns observed in BCC, depending on the lesion subtype, its location on the body, the patient's age, the size of the tumor, and skin phototype.
View Article and Find Full Text PDFImage Guidance is Associated with Improved Freedom From Recurrence After Superficial Radiation Therapy for Nonmelanoma Skin Cancer.
Adv Radiat Oncol
December 2024
Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
Purpose: This is the first study to quantify the 2-year freedom from recurrence for individuals with nonmelanoma skin cancer (NMSC) such as basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and squamous carcinoma in situ (SCCIS) treated with image guided superficial radiation therapy (IGSRT) versus SRT without image guidance.
Methods And Materials: This retrospective cohort study evaluates the 2-year freedom recurrence rate of NMSCs treated by IGSRT (March 2016 to January 2022) and compares it to existing data on NMSCs treated by SRT via 1 sample proportion tests. Individuals >18 years old with biopsy-proven SCC, SCCIS, and/or BCC treated with IGSRT were included in the study, and 1602 patients/2880 treated lesions were followed until January 14, 2022.
Analysis of tumoral, stromal and glycolitic markers in the response basal cell carcinoma and Bowen disease to photodynamic therapy in real life.
Photodiagnosis Photodyn Ther
December 2024
Department of Dermatology, Miguel Servet University Hospital, University of Zaragoza, IIS Aragón. Zaragoza, Spain.
Background: Photodynamic therapy (PDT) is a widely-used non-surgical treatment for non-melanoma skin cancers, including basal cell carcinoma (BCC), actinic keratoses (AK), and Bowen's disease (BD). PDT has high success rates, but various factors, can influence treatment response. This study investigates the clinical, histological, and molecular factors that affect the efficacy of methyl aminolevulinate PDT (MAL-PDT) for BCC and BD.
View Article and Find Full Text PDFManagement of a large basal cell carcinoma masquerading as psoriasis using Mohs and serial excisions.
SAGE Open Med Case Rep
December 2024
Division of Dermatology, McGill University, Montreal, QC, Canada.
Article Synopsis
- Basal cell carcinoma (BCC) is the most prevalent form of skin cancer, often manifesting as a scaly red patch, particularly in its superficial subtype.
- The case report highlights an elderly patient whose large BCC on the left scalp was mistakenly treated as plaque psoriasis for years.
- It emphasizes the importance of scouting biopsies for accurate cancer mapping and discusses serial excisions via Mohs micrographic surgery as an effective treatment option for large BCCs located in high-tension areas.
Long-term outcome of photodynamic therapy with hexyl aminolevulinate, 5-aminolevulinic acid nanoemulsion and methyl aminolevulinate for low-risk Basal Cell Carcinomas.
Photodiagnosis Photodyn Ther
December 2024
Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Region Västra Götaland, Sahlgrenska University Hospital, Department of Clinical Pathology, Gothenburg, Sweden.
Background: Non-surgical treatments are cost-effective options for low-risk basal cell carcinomas (BCCs) i.e. superficial or small nodular BCCs located outside the high-risk locations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!